Abrupt severe hypertension, rapidly progressive acute kidney injury, retinal changes, pulmonary edema, and microangiopathic hemolytic anemia in a patient with diffuse systemic sclerosis are characteristic of scleroderma renal crisis.

Why the Other Options Are Incorrect

• A. Lupus nephritis: Usually presents with immune-complex glomerulonephritis, active urinary sediment, low complement, and lupus serology.
• C. Chronic essential hypertension: Does not explain the sudden renal failure and microangiopathic hemolysis.
• D. Minimal-change disease: Causes nephrotic proteinuria without malignant hypertension or schistocytes.
• E. Primary hyperaldosteronism: Usually causes hypertension with hypokalemia rather than acute renal failure and hemolysis.

Clinical safety point Do not avoid ACE inhibitors simply because the patient already has severe acute kidney injury

An ACE inhibitor, commonly a rapidly titratable agent such as captopril, should be started immediately. Treatment should not be withheld merely because creatinine is elevated. EULAR recommendations identify immediate ACE-inhibitor therapy as the central treatment for scleroderma renal crisis.

Why the Other Options Are Incorrect

• A. High-dose prednisone: Glucocorticoids can increase the risk of renal crisis.
• C. Beta blocker alone: Does not address the disease’s renin-mediated vasoconstrictive process.
• D. Spironolactone alone: Is inadequate for this emergency.
• B. Cyclophosphamide: Is not a substitute for immediate blood-pressure control.

Clinical safety point Do not avoid ACE inhibitors simply because the patient already has severe acute kidney injury

Dialysis may be required during the acute phase, but ACE-inhibitor treatment is generally continued when blood pressure and potassium permit because renal recovery may occur over time.

Why the other options are less appropriate

• A. Stop it permanently: is less consistent with the full clinical context and is not the single best answer.
• B. Replace it with licorice extract: is less consistent with the full clinical context and is not the single best answer.
• D. Replace it with a potassium supplement: is less consistent with the full clinical context and is not the single best answer.
• E. Delay all antihypertensive therapy until dialysis is discontinued: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not avoid ACE inhibitors simply because the patient already has severe acute kidney injury

Systemic glucocorticoid exposure, particularly at higher doses, is associated with increased risk of scleroderma renal crisis. Patients receiving glucocorticoids require careful blood-pressure and renal monitoring.

Why the other options are less appropriate

• A. Topical aloe vera: is less consistent with the full clinical context and is not the single best answer.
• B. Vitamin B12 supplementation: is less consistent with the full clinical context and is not the single best answer.
• C. Psyllium: is less consistent with the full clinical context and is not the single best answer.
• E. Dietary fibre: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not avoid ACE inhibitors simply because the patient already has severe acute kidney injury

Bilateral hilar lymphadenopathy, uveitis, skin lesions, parotid involvement, hypercalciuria, and PTH-independent hypercalcemia strongly suggest multisystem sarcoidosis.

Why the other options are less appropriate

• B. Primary hyperparathyroidism: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Multiple myeloma: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Tuberculosis confirmed by calcium level: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Vitamin D deficiency: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Serum ACE is neither sufficiently sensitive nor sufficiently specific to confirm sarcoidosis by itself

Activated macrophages within granulomas can express 1-alpha-hydroxylase, increasing active vitamin D production and intestinal calcium absorption.

Why the other options are less appropriate

• A. Autonomous parathyroid hormone production: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. Isolated renal calcium retention caused by aldosterone: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Complete absence of vitamin D absorption: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• D. Excess calcitonin production: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Serum ACE is neither sufficiently sensitive nor sufficiently specific to confirm sarcoidosis by itself

The diagnosis rests on a compatible clinical presentation, nonnecrotizing granulomatous inflammation when tissue is required, and exclusion of infections, malignancy, occupational disease, and other granulomatous conditions.

Why the other options are less appropriate

• B. Serum ACE level alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Chest radiograph alone in every patient: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Calcium level alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Empiric treatment without considering infection or malignancy: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Serum ACE is neither sufficiently sensitive nor sufficiently specific to confirm sarcoidosis by itself

Vitamin D supplementation and increased ultraviolet exposure can worsen calcium abnormalities in susceptible patients. Symptomatic hypercalcemia or organ-threatening sarcoidosis may require systemic treatment.

Why the other options are less appropriate

• A. Begin high-dose vitamin D immediately: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Begin a calcium-based antacid several times daily: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Increase dairy intake substantially: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Replace medical treatment with turmeric: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Serum ACE is neither sufficiently sensitive nor sufficiently specific to confirm sarcoidosis by itself

Proteinuria, hypertension, acute kidney dysfunction, hematuria, red-cell casts, hypocomplementemia, and rising anti-dsDNA antibodies indicate active immune-complex lupus nephritis.

Why the other options are less appropriate

• A. Diabetic nephropathy: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Uncomplicated cystitis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Minimal-change disease caused by exercise: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Renal stone without glomerular disease: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not diagnose a urinary infection solely because blood and protein are present in the urine when red-cell casts indicate glomerular inflammation

Kidney biopsy identifies the histologic class, activity, chronicity, and additional renal lesions. These findings guide treatment and prognosis.

Why the other options are less appropriate

• A. Serum uric acid: is less consistent with the full clinical context and is not the single best answer.
• B. Plain abdominal radiograph: is less consistent with the full clinical context and is not the single best answer.
• C. Urine culture only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Renal ultrasound alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not diagnose a urinary infection solely because blood and protein are present in the urine when red-cell casts indicate glomerular inflammation

Proliferative lupus nephritis generally requires glucocorticoids plus immunosuppressive treatment such as mycophenolate-based or cyclophosphamide-based therapy. Current KDIGO guidance also incorporates selected combination regimens based on disease severity and patient factors.

Why the other options are less appropriate

• A. Discontinue all treatment and repeat testing in one year: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. NSAID monotherapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Antibiotics without evidence of infection: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. High-protein supplements alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not diagnose a urinary infection solely because blood and protein are present in the urine when red-cell casts indicate glomerular inflammation

Mycophenolate is teratogenic and requires reliable contraception and planned transition to a pregnancy-compatible regimen before conception. Hydroxychloroquine is generally continued in lupus unless contraindicated.

Why the other options are less appropriate

• A. Folic acid: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Hydroxychloroquine: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Calcium carbonate: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Acetaminophen used occasionally: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not diagnose a urinary infection solely because blood and protein are present in the urine when red-cell casts indicate glomerular inflammation

An ascitic-fluid neutrophil count of at least 250 cells/mm³ supports spontaneous bacterial peritonitis and warrants immediate treatment, even when culture results are pending.

Why the other options are less appropriate

• A. Nephrotic syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Uncomplicated sterile ascites: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Irritable bowel syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Acute pancreatitis confirmed by paracentesis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not wait for a positive ascitic culture when the neutrophil count is diagnostic

SBP requires prompt antimicrobial therapy. Albumin is used in selected patients to reduce the risk of worsening renal dysfunction. Treatment must not wait for culture positivity.

Why the other options are less appropriate

• B. Wait for a positive culture: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Start an herbal antimicrobial tincture: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Give an NSAID for abdominal pain: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Increase diuretic doses despite hypotension and kidney injury: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not wait for a positive ascitic culture when the neutrophil count is diagnostic

HRS-AKI is a functional renal failure occurring in advanced cirrhosis after other causes of acute kidney injury, including hypovolemia, shock, nephrotoxicity, and structural renal disease, have been assessed.

Why the other options are less appropriate

• A. Poststreptococcal glomerulonephritis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Renal-cell carcinoma: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Chronic pyelonephritis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Nephrolithiasis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not wait for a positive ascitic culture when the neutrophil count is diagnostic

Appropriate vasoconstrictor therapy combined with albumin is used for HRS-AKI. Liver transplantation is the definitive therapy for eligible patients.

Why the other options are less appropriate

• A. Fluid restriction without hemodynamic treatment: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. NSAID therapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. ACE-inhibitor initiation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Botanical diuretics alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not wait for a positive ascitic culture when the neutrophil count is diagnostic

Rapid thrombosis involving several organ systems over a short period in a patient with antiphospholipid antibodies is characteristic of catastrophic antiphospholipid syndrome.

Why the other options are less appropriate

• A. Immune thrombocytopenia: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Hemophilia: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Uncomplicated postoperative DVT: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Disseminated cancer without thrombosis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not treat CAPS as an isolated DVT when the kidneys, lungs, skin, brain, and hematologic system are becoming involved simultaneously

CAPS produces rapidly developing small- and large-vessel thrombosis affecting three or more organ systems, commonly involving the kidneys, lungs, brain, skin, heart, or gastrointestinal tract.

Why the other options are less appropriate

• B. The presence of leg pain: is less consistent with the full clinical context and is not the single best answer.
• C. Recent surgery alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Mild thrombocytopenia alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Positive antinuclear antibodies alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not treat CAPS as an isolated DVT when the kidneys, lungs, skin, brain, and hematologic system are becoming involved simultaneously

First-line CAPS treatment uses combination therapy, often described as triple therapy: anticoagulation, glucocorticoids, and plasma exchange and/or IV immunoglobulin. The precipitating infection, surgery-related complication, or lupus flare must also be treated.

Why the other options are less appropriate

• A. Platelet transfusion as sole treatment: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Aspirin alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Warfarin loading without acute heparin therapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Observation until thrombosis stops: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not treat CAPS as an isolated DVT when the kidneys, lungs, skin, brain, and hematologic system are becoming involved simultaneously

Products with potential antiplatelet activity may increase bleeding concerns when combined with therapeutic anticoagulation.

Why the other options are less appropriate

• A. Standard oral rehydration solution: is less consistent with the full clinical context and is not the single best answer.
• B. Psyllium used with adequate spacing: is less consistent with the full clinical context and is not the single best answer.
• C. Vitamin B12: is less consistent with the full clinical context and is not the single best answer.
• D. Inulin: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not treat CAPS as an isolated DVT when the kidneys, lungs, skin, brain, and hematologic system are becoming involved simultaneously

Destructive upper-airway disease, pulmonary nodules or alveolar hemorrhage, rapidly progressive glomerulonephritis, and PR3-ANCA positivity strongly suggest granulomatosis with polyangiitis.

Why the other options are less appropriate

• A. Uncomplicated bacterial sinusitis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Isolated IgA nephropathy: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Pulmonary embolism alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Goodpasture syndrome without upper-airway disease: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not interpret hemoptysis, falling hemoglobin, and diffuse opacities as uncomplicated pneumonia when red-cell casts and acute kidney injury indicate a pulmonary–renal syndrome

Pulmonary hemorrhage and rapidly progressive glomerulonephritis are organ-threatening manifestations requiring immediate specialist treatment.

Why the other options are less appropriate

• A. High-dose echinacea: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Oral antibiotics alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Nasal saline and follow-up in six months: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Delay treatment until permanent renal failure occurs: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not interpret hemoptysis, falling hemoglobin, and diffuse opacities as uncomplicated pneumonia when red-cell casts and acute kidney injury indicate a pulmonary–renal syndrome

Rituximab or cyclophosphamide is used with glucocorticoids for severe GPA or microscopic polyangiitis. The ACR/Vasculitis Foundation guideline conditionally favors rituximab over cyclophosphamide for remission induction in severe disease.

Why the other options are less appropriate

• B. Hydroxychloroquine alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Methotrexate alone despite severe kidney disease: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. NSAID therapy: is less consistent with the full clinical context and is not the single best answer.
• E. Colchicine alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not interpret hemoptysis, falling hemoglobin, and diffuse opacities as uncomplicated pneumonia when red-cell casts and acute kidney injury indicate a pulmonary–renal syndrome

Pneumocystis prophylaxis is generally recommended during cyclophosphamide or rituximab treatment and significant accompanying glucocorticoid exposure, unless contraindicated.

Why the other options are less appropriate

• A. Warfarin prophylaxis in every patient: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Live vaccination during maximal immunosuppression: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Routine antifungal treatment in every patient: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. High-dose potassium: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not interpret hemoptysis, falling hemoglobin, and diffuse opacities as uncomplicated pneumonia when red-cell casts and acute kidney injury indicate a pulmonary–renal syndrome

The delayed onset after a high-risk medication, fever, extensive rash, facial edema, eosinophilia, lymphadenopathy, hepatitis, and kidney injury indicate DRESS syndrome.

Why the other options are less appropriate

• A. Stevens–Johnson syndrome confirmed by eosinophilia: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Simple urticaria: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Scarlet fever: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Psoriasis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not continue the culprit medication merely because the rash is being treated with antihistamines or topical corticosteroids

Immediate and permanent withdrawal of the suspected medication is essential. Serious hepatic, renal, pulmonary, cardiac, or hematologic involvement requires urgent specialist management.

Why the other options are less appropriate

• A. Continue allopurinol while adding an antihistamine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Reduce allopurinol for one week: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Rechallenge the patient after the rash improves: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Begin a detoxification diet: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not continue the culprit medication merely because the rash is being treated with antihistamines or topical corticosteroids

Internal-organ injury is a defining concern in DRESS. The liver is commonly affected, but renal, pulmonary, cardiac, neurologic, and hematologic complications can occur.

Why the other options are less appropriate

• A. One small patch of erythema: is less consistent with the full clinical context and is not the single best answer.
• B. Mild localized itching: is less consistent with the full clinical context and is not the single best answer.
• D. Dry skin only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Rash resolving despite continued medication: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not continue the culprit medication merely because the rash is being treated with antihistamines or topical corticosteroids

Management is severity-based. Significant organ involvement commonly leads to systemic glucocorticoid treatment, although treatment must be individualized and infection carefully assessed. Contemporary EAACI work emphasizes clinical diagnosis and severity-based management.

Why the other options are less appropriate

• B. Topical moisturizer as the only treatment: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Immediate allopurinol desensitization: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Oral iron: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. High-dose vitamin A: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not continue the culprit medication merely because the rash is being treated with antihistamines or topical corticosteroids

Anemia, renal impairment, hypercalcemia, lytic bone lesions, a protein gap, rouleaux formation, and markedly elevated monoclonal light chains are characteristic of active multiple myeloma.

Why the other options are less appropriate

• A. Primary hyperparathyroidism alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Metastatic prostate cancer confirmed by calcium elevation: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Iron-deficiency anemia: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Polymyalgia rheumatica: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not dismiss severe renal failure because the routine urine dipstick shows only modest protein

Monoclonal-protein testing and bone-marrow evaluation establish the plasma-cell disorder. Whole-body imaging identifies lytic lesions and other skeletal complications.

Why the other options are less appropriate

• A. PSA alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Stool culture and colonoscopy only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. ANA testing alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Serum calcium alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not dismiss severe renal failure because the routine urine dipstick shows only modest protein

Rapid reduction of nephrotoxic free light chains is critical. Bortezomib-based therapy and high-dose dexamethasone are central approaches in myeloma-related renal impairment, accompanied by hydration and withdrawal of nephrotoxins. Mechanical light-chain-removal procedures do not replace effective anti-myeloma therapy.

Why the other options are less appropriate

• A. Delay treatment until permanent dialysis is required: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Oral calcium supplementation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. NSAID treatment for bone pain: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Plasmapheresis as the sole treatment: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not dismiss severe renal failure because the routine urine dipstick shows only modest protein

NSAIDs can reduce renal perfusion and aggravate acute kidney injury. Contrast exposure and other nephrotoxins should also be minimized when possible.

Why the other options are less appropriate

• A. Necessary antimicrobial treatment adjusted for renal function: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Acetaminophen within appropriate dosing limits: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Prescribed anti-myeloma therapy: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Isotonic fluid when clinically appropriate: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not dismiss severe renal failure because the routine urine dipstick shows only modest protein

Nephrotic proteinuria, restrictive cardiomyopathy, autonomic neuropathy, peripheral neuropathy, macroglossia, periorbital purpura, and a monoclonal light-chain abnormality strongly suggest systemic AL amyloidosis.

Why the other options are less appropriate

• B. Uncomplicated hypertensive heart disease: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Nephrotic syndrome from isolated minimal-change disease: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Constrictive pericarditis confirmed by macroglossia: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Primary adrenal insufficiency: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not assume a positive monoclonal protein proves that all cardiac amyloidosis is AL; tissue typing and an integrated diagnostic assessment remain essential

A combination of serum immunofixation, urine immunofixation, and serum free-light-chain testing improves detection of the underlying monoclonal protein. Serum protein electrophoresis alone is insufficient. The 2026 ASH diagnostic guideline emphasizes comprehensive paraprotein testing in suspected AL amyloidosis.

Why the other options are less appropriate

• A. Bone scan alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Serum protein electrophoresis alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Urine dipstick alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Troponin alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not assume a positive monoclonal protein proves that all cardiac amyloidosis is AL; tissue typing and an integrated diagnostic assessment remain essential

Congo-red-positive deposits showing characteristic birefringence confirm amyloid. Accurate typing, preferably using a validated method such as mass spectrometry, is essential because treatment differs greatly between AL and transthyretin amyloidosis.

Why the other options are less appropriate

• A. Echocardiography alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Serum free-light-chain ratio alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Bone-density testing: is less consistent with the full clinical context and is not the single best answer.
• E. ANA testing: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not assume a positive monoclonal protein proves that all cardiac amyloidosis is AL; tissue typing and an integrated diagnostic assessment remain essential

Treatment aims to suppress production of the pathogenic light chain while cautiously managing cardiac, renal, neurologic, gastrointestinal, and other organ complications.

Why the other options are less appropriate

• A. Botanical cardiac stimulants: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Diuretics alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. High-dose calcium: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Anticoagulation in every patient regardless of rhythm or bleeding risk: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not assume a positive monoclonal protein proves that all cardiac amyloidosis is AL; tissue typing and an integrated diagnostic assessment remain essential

Persistent high fever, splenomegaly, pancytopenia, extreme hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, hepatitis, and neurologic dysfunction strongly suggest HLH.

Why the other options are less appropriate

• A. Iron-deficiency anemia: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Immune thrombocytopenia alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Uncomplicated viral syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Hereditary hemochromatosis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not wait for visible hemophagocytosis or fulfillment of every possible criterion before escalating a rapidly deteriorating patient

The HLH-2004 framework permits diagnosis through a compatible molecular finding or fulfillment of at least five of eight criteria, including fever, splenomegaly, cytopenias, triglyceride or fibrinogen abnormalities, hemophagocytosis, reduced NK-cell activity, elevated ferritin, and elevated soluble CD25.

Why the other options are less appropriate

• B. Ferritin elevation alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Bone-marrow hemophagocytosis alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Positive EBV serology alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Splenomegaly alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not wait for visible hemophagocytosis or fulfillment of every possible criterion before escalating a rapidly deteriorating patient

Hemophagocytosis may be absent early, can be missed during sampling, and is not specific to HLH. Treatment should not be delayed in a critically ill patient whose overall clinical pattern strongly supports the diagnosis.

Why the other options are less appropriate

• A. Yes, because marrow findings are always present early: is less consistent with the full clinical context and is not the single best answer.
• B. Yes, in every patient: is less consistent with the full clinical context and is not the single best answer.
• C. Yes, unless ferritin is normal: is less consistent with the full clinical context and is not the single best answer.
• D. Yes, unless the patient is a child: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not wait for visible hemophagocytosis or fulfillment of every possible criterion before escalating a rapidly deteriorating patient

Adult HLH is a medical emergency. Treatment may include dexamethasone, etoposide, or other targeted immunomodulatory therapy depending on severity and the precipitating infection, malignancy, or autoimmune disease. The Histiocyte Society’s adult recommendations stress rapid diagnosis, control of hyperinflammation, and treatment of the trigger.

Why the other options are less appropriate

• A. Wait several weeks for every specialized test: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Oral iron alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Treat the fever with acetaminophen only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Begin an immune-stimulating supplement: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not wait for visible hemophagocytosis or fulfillment of every possible criterion before escalating a rapidly deteriorating patient

Daily spiking fever, inflammatory arthritis, sore throat, an evanescent salmon-coloured rash, marked hyperferritinemia, and negative ANA and rheumatoid factor suggest Still disease. The subsequent cytopenias, hepatitis, hypofibrinogenemia, hypertriglyceridemia, neurologic deterioration, and extreme ferritin elevation indicate macrophage activation syndrome.

Why the other options are less appropriate

• A. Rheumatoid arthritis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Uncomplicated viral upper-respiratory infection: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Iron-overload syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Primary immune thrombocytopenia: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Extreme ferritin elevation does not mean the patient needs iron supplementation. Current EULAR/PReS recommendations emphasize early recognition of MAS and rapid cytokine-directed and glucocorticoid-based treatment for severe Still disease

MAS produces uncontrolled macrophage and T-cell activation. Cytopenias, falling fibrinogen, liver dysfunction, coagulopathy, hypertriglyceridemia, and rapidly rising ferritin are major warning findings.

Why the other options are less appropriate

• A. Increasing albumin concentration: is less consistent with the full clinical context and is not the single best answer.
• B. Mild isolated elevation of ESR: is less consistent with the full clinical context and is not the single best answer.
• C. Stable blood counts with improving liver enzymes: is less consistent with the full clinical context and is not the single best answer.
• E. Isolated iron deficiency: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Extreme ferritin elevation does not mean the patient needs iron supplementation. Current EULAR/PReS recommendations emphasize early recognition of MAS and rapid cytokine-directed and glucocorticoid-based treatment for severe Still disease

ESR depends partly on fibrinogen. During MAS, fibrinogen may fall because of consumption and liver dysfunction, producing a paradoxically low or falling ESR despite severe inflammation.

Why the other options are less appropriate

• A. ESR always becomes normal in bacterial infection: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. Ferritin directly destroys erythrocytes in the test tube: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• D. Platelet destruction falsely raises albumin: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. ESR is unrelated to plasma proteins: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Extreme ferritin elevation does not mean the patient needs iron supplementation. Current EULAR/PReS recommendations emphasize early recognition of MAS and rapid cytokine-directed and glucocorticoid-based treatment for severe Still disease

MAS is a life-threatening hyperinflammatory emergency. Management commonly includes high-dose glucocorticoids and rapid consideration of cytokine-directed treatment, particularly IL-1 inhibition, while infection and other triggers are investigated and treated.

Why the other options are less appropriate

• A. Begin an immune-stimulating botanical formula: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. NSAID monotherapy and outpatient follow-up: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Oral iron for the elevated ferritin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Delay treatment until bone-marrow hemophagocytosis is demonstrated: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Extreme ferritin elevation does not mean the patient needs iron supplementation. Current EULAR/PReS recommendations emphasize early recognition of MAS and rapid cytokine-directed and glucocorticoid-based treatment for severe Still disease

Adult-onset asthma, sinus disease, marked eosinophilia, transient pulmonary infiltrates, palpable purpura, mononeuritis multiplex, renal abnormalities, and myocarditis are characteristic of EGPA.

Why the other options are less appropriate

• B. Uncomplicated allergic asthma: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Granulomatosis with polyangiitis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Hypereosinophilia caused solely by seasonal allergy: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Chronic obstructive pulmonary disease: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not classify marked eosinophilia with neuropathy, purpura, and myocarditis as uncomplicated allergic asthma. The ACR/Vasculitis Foundation guideline distinguishes severe EGPA requiring glucocorticoid-based immunosuppressive induction from nonsevere disease in which mepolizumab may be used

Cardiac involvement can cause arrhythmia, heart failure, and death. Progressive vasculitic neuropathy also represents significant organ damage requiring urgent treatment.

Why the other options are less appropriate

• A. Seasonal sneezing: is less consistent with the full clinical context and is not the single best answer.
• B. Mild nasal congestion: is less consistent with the full clinical context and is not the single best answer.
• D. Stable inhaler use: is less consistent with the full clinical context and is not the single best answer.
• E. Mild peripheral eosinophilia without symptoms: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not classify marked eosinophilia with neuropathy, purpura, and myocarditis as uncomplicated allergic asthma. The ACR/Vasculitis Foundation guideline distinguishes severe EGPA requiring glucocorticoid-based immunosuppressive induction from nonsevere disease in which mepolizumab may be used

Severe EGPA generally requires systemic glucocorticoids plus an induction agent such as cyclophosphamide or rituximab. Mepolizumab is particularly useful in selected nonsevere, relapsing, or eosinophilic disease but is not a substitute for intensive induction treatment in life-threatening vasculitis.

Why the other options are less appropriate

• B. Mepolizumab monotherapy for acute myocarditis: is less consistent with the full clinical context and is not the single best answer.
• C. Inhaled corticosteroid alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Antihistamine monotherapy: is less consistent with the full clinical context and is not the single best answer.
• E. Antibiotics without evidence of infection: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not classify marked eosinophilia with neuropathy, purpura, and myocarditis as uncomplicated allergic asthma. The ACR/Vasculitis Foundation guideline distinguishes severe EGPA requiring glucocorticoid-based immunosuppressive induction from nonsevere disease in which mepolizumab may be used

Only a subset of patients with EGPA are ANCA-positive. Diagnosis depends on the complete clinical pattern rather than ANCA testing alone.

Why the other options are less appropriate

• A. ANCA distinguishes bacterial from viral pneumonia: is less consistent with the full clinical context and is not the single best answer.
• B. Every patient with EGPA must have PR3-ANCA: is less consistent with the full clinical context and is not the single best answer.
• C. ANCA determines the diagnosis without clinical findings: is less consistent with the full clinical context and is not the single best answer.
• D. ANCA is always positive during asthma attacks: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not classify marked eosinophilia with neuropathy, purpura, and myocarditis as uncomplicated allergic asthma. The ACR/Vasculitis Foundation guideline distinguishes severe EGPA requiring glucocorticoid-based immunosuppressive induction from nonsevere disease in which mepolizumab may be used

Medium-vessel disease causing mesenteric ischemia, renovascular hypertension, skin nodules, livedo reticularis, mononeuritis multiplex, and angiographic microaneurysms is characteristic of PAN.

Why the other options are less appropriate

• A. Granulomatosis with polyangiitis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Microscopic polyangiitis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Systemic lupus erythematosus: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Infective endocarditis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Pulmonary capillaritis and glomerulonephritis suggest another vasculitis, not classic PAN. The ACR/Vasculitis Foundation PAN guideline supports tissue biopsy or vascular imaging and severity-based immunosuppressive treatment

PAN affects medium and small muscular arteries but typically spares glomerular capillaries. Hematuria may occur from renal ischemia, but an active glomerulonephritic sediment is not typical.

Why the other options are less appropriate

• A. Strong MPO-ANCA positivity: is less consistent with the full clinical context and is not the single best answer.
• B. Red-cell casts and pulmonary capillaritis: is less consistent with the full clinical context and is not the single best answer.
• C. Diffuse alveolar hemorrhage: is less consistent with the full clinical context and is not the single best answer.
• E. Isolated asthma: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Pulmonary capillaritis and glomerulonephritis suggest another vasculitis, not classic PAN. The ACR/Vasculitis Foundation PAN guideline supports tissue biopsy or vascular imaging and severity-based immunosuppressive treatment

Biopsy may show necrotizing inflammation of medium or small muscular arteries. Angiography is particularly useful when abdominal or renal arterial involvement is suspected.

Why the other options are less appropriate

• A. Serum ESR alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. ANA testing alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Routine chest radiograph: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Stool occult-blood testing alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Pulmonary capillaritis and glomerulonephritis suggest another vasculitis, not classic PAN. The ACR/Vasculitis Foundation PAN guideline supports tissue biopsy or vascular imaging and severity-based immunosuppressive treatment

Treatment must address both the vasculitis and active hepatitis B. Antiviral therapy is central, with carefully selected short-term immunosuppression and plasma exchange in some severe presentations.

Why the other options are less appropriate

• A. Long-term high-dose glucocorticoid monotherapy without antiviral treatment: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Discontinue hepatitis testing after diagnosis: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Treat only the hypertension: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Use botanical immune stimulants: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Pulmonary capillaritis and glomerulonephritis suggest another vasculitis, not classic PAN. The ACR/Vasculitis Foundation PAN guideline supports tissue biopsy or vascular imaging and severity-based immunosuppressive treatment

Characteristic dermatomyositis skin findings, little muscle weakness, normal CK, anti-MDA5 positivity, hyperferritinemia, and rapidly progressive ILD indicate this high-risk phenotype.

Why the other options are less appropriate

• A. Systemic sclerosis without lung disease: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Uncomplicated eczema: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Bacterial pneumonia alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Polymyalgia rheumatica: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Normal muscle enzymes do not exclude life-threatening dermatomyositis-associated lung disease. The ACR/CHEST ILD guideline conditionally recommends upfront combination treatment for rapidly progressive autoimmune ILD, with triple therapy considered when anti-MDA5 disease is suspected

Anti-MDA5 disease may be clinically amyopathic, meaning classic skin and systemic manifestations occur without substantial muscle weakness or CK elevation.

Why the other options are less appropriate

• B. Gottron papules: is less consistent with the full clinical context and is not the single best answer.
• C. Heliotrope rash: is less consistent with the full clinical context and is not the single best answer.
• D. Nailfold abnormalities: is less consistent with the full clinical context and is not the single best answer.
• E. Anti-MDA5 antibodies: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Normal muscle enzymes do not exclude life-threatening dermatomyositis-associated lung disease. The ACR/CHEST ILD guideline conditionally recommends upfront combination treatment for rapidly progressive autoimmune ILD, with triple therapy considered when anti-MDA5 disease is suspected

Rapidly progressive anti-MDA5 ILD carries substantial mortality. Current guidance supports early combination immunosuppression, often involving glucocorticoids plus additional agents, rather than waiting for failure of prolonged monotherapy.

Why the other options are less appropriate

• A. Observe until pulmonary fibrosis is irreversible: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Topical corticosteroid alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Antibiotics alone despite negative infection evaluation: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Begin vigorous aerobic exercise: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Normal muscle enzymes do not exclude life-threatening dermatomyositis-associated lung disease. The ACR/CHEST ILD guideline conditionally recommends upfront combination treatment for rapidly progressive autoimmune ILD, with triple therapy considered when anti-MDA5 disease is suspected

HRCT identifies ground-glass opacity, consolidation, organizing-pneumonia patterns, and fibrotic change. Pulmonary-function testing and oxygen assessment provide additional severity information.

Why the other options are less appropriate

• A. Plain hand radiograph: is less consistent with the full clinical context and is not the single best answer.
• C. Abdominal ultrasound: is less consistent with the full clinical context and is not the single best answer.
• D. Colonoscopy: is less consistent with the full clinical context and is not the single best answer.
• E. Bone-density testing: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Normal muscle enzymes do not exclude life-threatening dermatomyositis-associated lung disease. The ACR/CHEST ILD guideline conditionally recommends upfront combination treatment for rapidly progressive autoimmune ILD, with triple therapy considered when anti-MDA5 disease is suspected

Recurrent oral and genital ulcers, uveitis, inflammatory skin lesions, and cerebral venous thrombosis form a characteristic Behçet pattern.

Why the other options are less appropriate

• B. Migraine with aura: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Multiple sclerosis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Uncomplicated aphthous stomatitis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Giant-cell arteritis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not treat the clot while ignoring the underlying systemic vasculitis. EULAR recommendations prioritize immunosuppressive control of vascular inflammation and individualized decisions regarding anticoagulation

Thrombosis in Behçet syndrome is strongly associated with vascular inflammation. Management therefore focuses on controlling inflammation rather than viewing the event as an ordinary unprovoked clot.

Why the other options are less appropriate

• A. Primary platelet deficiency: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Isolated dietary vitamin K excess: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Atherosclerotic plaque rupture: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Mechanical cervical misalignment: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not treat the clot while ignoring the underlying systemic vasculitis. EULAR recommendations prioritize immunosuppressive control of vascular inflammation and individualized decisions regarding anticoagulation

Acute cerebral venous involvement generally requires rapid control of vascular inflammation. Additional immunosuppressive treatment is individualized according to severity, recurrence, and other organ involvement.

Why the other options are less appropriate

• A. Cervical manipulation for headache: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Aspirin alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Anticoagulation without evaluating vascular inflammation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Observation because venous thrombosis is self-limited: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not treat the clot while ignoring the underlying systemic vasculitis. EULAR recommendations prioritize immunosuppressive control of vascular inflammation and individualized decisions regarding anticoagulation

Anticoagulation is individualized in Behçet thrombosis. Pulmonary-artery aneurysms can cause catastrophic hemorrhage, so vascular imaging and specialist assessment may be required before anticoagulation.

Why the other options are less appropriate

• A. Skin-prick allergy testing: is less consistent with the full clinical context and is not the single best answer.
• B. Serum vitamin B12 level: is less consistent with the full clinical context and is not the single best answer.
• D. Bone-density testing: is less consistent with the full clinical context and is not the single best answer.
• E. Stool culture: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not treat the clot while ignoring the underlying systemic vasculitis. EULAR recommendations prioritize immunosuppressive control of vascular inflammation and individualized decisions regarding anticoagulation

Acute liver failure in a young patient, disproportionately low alkaline phosphatase, Coombs-negative hemolytic anemia, renal dysfunction, low ceruloplasmin, and Kayser–Fleischer rings strongly suggest Wilson disease.

Why the other options are less appropriate

• A. Gilbert syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Autoimmune hemolytic anemia: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Uncomplicated acute hepatitis A: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Iron-deficiency anemia: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not manage Wilson-related acute liver failure with outpatient chelation or zinc alone. AASLD and EASL guidance emphasize multidisciplinary diagnosis and immediate transplant-centre evaluation for Wilson-related acute liver failure

Wilson-related acute liver failure can progress rapidly and carries a poor prognosis without transplantation. Transplant evaluation must not be delayed for completion of every confirmatory test.

Why the other options are less appropriate

• B. Outpatient zinc therapy with follow-up in three months: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Begin iron supplementation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Perform routine exercise testing: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Delay referral until genetic testing returns: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not manage Wilson-related acute liver failure with outpatient chelation or zinc alone. AASLD and EASL guidance emphasize multidisciplinary diagnosis and immediate transplant-centre evaluation for Wilson-related acute liver failure

Diagnosis integrates clinical findings, ceruloplasmin, urinary copper, eye examination, hepatic copper when safe, and ATP7B genetic testing. No single test is sufficient in every patient.

Why the other options are less appropriate

• A. ANA alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Serum ferritin alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Stool copper alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Serum sodium alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not manage Wilson-related acute liver failure with outpatient chelation or zinc alone. AASLD and EASL guidance emphasize multidisciplinary diagnosis and immediate transplant-centre evaluation for Wilson-related acute liver failure

Plasma exchange and other extracorporeal support may reduce circulating copper and stabilize selected patients while urgent transplantation is arranged. They do not replace transplant assessment.

Why the other options are less appropriate

• A. High-dose oral calcium: is less consistent with the full clinical context and is not the single best answer.
• C. Routine phlebotomy: is less consistent with the full clinical context and is not the single best answer.
• D. Intramuscular iron: is less consistent with the full clinical context and is not the single best answer.
• E. An herbal liver cleanse: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not manage Wilson-related acute liver failure with outpatient chelation or zinc alone. AASLD and EASL guidance emphasize multidisciplinary diagnosis and immediate transplant-centre evaluation for Wilson-related acute liver failure

Severe neurovisceral abdominal pain, autonomic instability, psychiatric symptoms, motor neuropathy, hyponatremia, medication exposure, fasting, and darkening urine suggest an acute hepatic porphyria.

Why the other options are less appropriate

• A. Hereditary coproporphyria with mandatory skin lesions: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Acute appendicitis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Diabetic ketoacidosis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Lead poisoning confirmed by constipation alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point AIP does not characteristically cause photosensitive blistering skin lesions. AGA guidance identifies urinary porphobilinogen testing during symptoms, removal of triggers, carbohydrate support, and intravenous hemin as central management principles

Urinary porphobilinogen is markedly elevated during most acute attacks and is the key initial diagnostic test. Samples should be protected from light.

Why the other options are less appropriate

• A. ANA: is less consistent with the full clinical context and is not the single best answer.
• B. Serum ferritin: is less consistent with the full clinical context and is not the single best answer.
• C. Stool occult blood: is less consistent with the full clinical context and is not the single best answer.
• E. Serum amylase alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point AIP does not characteristically cause photosensitive blistering skin lesions. AGA guidance identifies urinary porphobilinogen testing during symptoms, removal of triggers, carbohydrate support, and intravenous hemin as central management principles

Severe attacks require intravenous hemin, withdrawal of precipitating medications, carbohydrate support, careful correction of hyponatremia, pain control, and respiratory monitoring.

Why the other options are less appropriate

• A. Oral iron: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Fluid restriction without sodium monitoring: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. High-protein fasting: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Stimulant laxatives alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point AIP does not characteristically cause photosensitive blistering skin lesions. AGA guidance identifies urinary porphobilinogen testing during symptoms, removal of triggers, carbohydrate support, and intravenous hemin as central management principles

Fasting, severe carbohydrate restriction, alcohol, hormonal changes, illness, and porphyrinogenic medications can precipitate attacks. Medication safety should be checked using a reliable porphyria-drug resource.

Why the other options are less appropriate

• A. Use all antiseizure medications interchangeably: is less consistent with the full clinical context and is not the single best answer.
• B. Follow repeated ketogenic fasts: is less consistent with the full clinical context and is not the single best answer.
• D. Avoid carbohydrates permanently: is less consistent with the full clinical context and is not the single best answer.
• E. Stop all prescribed medications abruptly: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point AIP does not characteristically cause photosensitive blistering skin lesions. AGA guidance identifies urinary porphobilinogen testing during symptoms, removal of triggers, carbohydrate support, and intravenous hemin as central management principles

Rapid tumour-cell breakdown releases potassium, phosphate, nucleic acids, and intracellular contents, causing hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia, and acute kidney injury.

Why the other options are less appropriate

• B. Hyperparathyroidism: does not explain the complete pattern of history, examination findings, and available investigations.
• C. SIADH: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Nephrotic syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Refeeding syndrome: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Allopurinol prevents new uric-acid formation but does not remove existing uric acid. Current TLS guidance emphasizes risk-based prevention, hydration, frequent biochemical monitoring, and rapid treatment with uric-acid-lowering therapy

Rasburicase enzymatically converts existing uric acid into a more soluble metabolite. Allopurinol prevents formation of additional uric acid but does not rapidly remove uric acid already present.

Why the other options are less appropriate

• A. Hydrochlorothiazide: is less consistent with the full clinical context and is not the single best answer.
• B. Allopurinol: is less consistent with the full clinical context and is not the single best answer.
• C. Spironolactone: is less consistent with the full clinical context and is not the single best answer.
• D. Calcium carbonate: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Allopurinol prevents new uric-acid formation but does not remove existing uric acid. Current TLS guidance emphasizes risk-based prevention, hydration, frequent biochemical monitoring, and rapid treatment with uric-acid-lowering therapy

Rasburicase can cause severe oxidative hemolysis and methemoglobinemia in G6PD deficiency.

Why the other options are less appropriate

• A. A patient with hyperuricemia: is less consistent with the full clinical context and is not the single best answer.
• B. A patient with lymphoma: is less consistent with the full clinical context and is not the single best answer.
• D. A patient receiving chemotherapy: is less consistent with the full clinical context and is not the single best answer.
• E. A patient with elevated LDH: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Allopurinol prevents new uric-acid formation but does not remove existing uric acid. Current TLS guidance emphasizes risk-based prevention, hydration, frequent biochemical monitoring, and rapid treatment with uric-acid-lowering therapy

Calcium is administered when significant symptoms such as tetany, seizure, or dangerous arrhythmia are present. Unnecessary calcium can increase tissue and renal calcium-phosphate deposition.

Why the other options are less appropriate

• A. Ignore severe tetany or arrhythmia: is less consistent with the full clinical context and is not the single best answer.
• B. Normalize calcium immediately with repeated large doses: is less consistent with the full clinical context and is not the single best answer.
• C. Begin high-dose vitamin D: is less consistent with the full clinical context and is not the single best answer.
• D. Give calcium-containing antacids: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Allopurinol prevents new uric-acid formation but does not remove existing uric acid. Current TLS guidance emphasizes risk-based prevention, hydration, frequent biochemical monitoring, and rapid treatment with uric-acid-lowering therapy

Acute hypermetabolism after exposure to succinylcholine or a volatile anesthetic, with rapidly increasing CO₂, rigidity, tachycardia, acidosis, hyperkalemia, rhabdomyolysis, and hyperthermia, is characteristic of malignant hyperthermia.

Why the other options are less appropriate

• B. Neuroleptic malignant syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Sepsis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Thyroid storm: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Acetaminophen does not correct malignant-hyperthermia physiology. MHAUS identifies immediate trigger discontinuation, hyperventilation, cooling when indicated, and rapid dantrolene administration as the core emergency response

Dantrolene reduces abnormal skeletal-muscle calcium release. It should be administered immediately while triggering agents are discontinued and resuscitative care begins.

Why the other options are less appropriate

• A. Acetaminophen: is less consistent with the full clinical context and is not the single best answer.
• B. Bromocriptine: is less consistent with the full clinical context and is not the single best answer.
• C. Cyproheptadine: is less consistent with the full clinical context and is not the single best answer.
• E. Naloxone: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Acetaminophen does not correct malignant-hyperthermia physiology. MHAUS identifies immediate trigger discontinuation, hyperventilation, cooling when indicated, and rapid dantrolene administration as the core emergency response

Hypercapnia despite increased minute ventilation is often an early manifestation. Marked hyperthermia may develop later.

Why the other options are less appropriate

• A. Mild postoperative itching: is less consistent with the full clinical context and is not the single best answer.
• C. Gradual iron deficiency: is less consistent with the full clinical context and is not the single best answer.
• D. Isolated constipation: is less consistent with the full clinical context and is not the single best answer.
• E. Low body temperature: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Acetaminophen does not correct malignant-hyperthermia physiology. MHAUS identifies immediate trigger discontinuation, hyperventilation, cooling when indicated, and rapid dantrolene administration as the core emergency response

The patient and close relatives may require genetic or contracture testing. The event must be documented clearly, and future anesthesia should use nontriggering techniques.

Why the other options are less appropriate

• A. Avoid all local anesthetics: is less consistent with the full clinical context and is not the single best answer.
• B. Future anesthesia requires no precautions: is less consistent with the full clinical context and is not the single best answer.
• D. Take prophylactic acetaminophen before surgery: is less consistent with the full clinical context and is not the single best answer.
• E. Use succinylcholine for all future procedures: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Acetaminophen does not correct malignant-hyperthermia physiology. MHAUS identifies immediate trigger discontinuation, hyperventilation, cooling when indicated, and rapid dantrolene administration as the core emergency response

Rapid psychiatric change followed by seizures, speech dysfunction, dyskinesias, reduced consciousness, and autonomic instability strongly suggests anti-NMDA receptor encephalitis.

Why the other options are less appropriate

• B. First-episode schizophrenia: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Neuroleptic malignant syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Substance intoxication: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Uncomplicated panic disorder: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point New psychosis accompanied by seizures and dyskinesias requires neurologic investigation. Canadian and international guidance supports early immunotherapy, CSF antibody testing, tumour screening, and tumour removal when applicable

CSF antibody testing is central to confirmation. Serum testing alone can produce misleading results and should be interpreted cautiously.

Why the other options are less appropriate

• A. Serum ANA alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Routine brain CT alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Urine culture: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Serum prolactin: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point New psychosis accompanied by seizures and dyskinesias requires neurologic investigation. Canadian and international guidance supports early immunotherapy, CSF antibody testing, tumour screening, and tumour removal when applicable

Early immunotherapy and removal of an associated ovarian teratoma improve the likelihood of recovery. Second-line immunotherapy is considered when first-line treatment is inadequate.

Why the other options are less appropriate

• A. Electroconvulsive therapy as the only treatment: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Antipsychotic monotherapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Antibiotics alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Observation until antibodies disappear: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point New psychosis accompanied by seizures and dyskinesias requires neurologic investigation. Canadian and international guidance supports early immunotherapy, CSF antibody testing, tumour screening, and tumour removal when applicable

Patients may develop arrhythmia, severe blood-pressure fluctuations, fever, respiratory failure, aspiration, and prolonged seizures.

Why the other options are less appropriate

• A. Chronic constipation alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Mild acne: is less consistent with the full clinical context and is not the single best answer.
• C. Seasonal allergic rhinitis: is less consistent with the full clinical context and is not the single best answer.
• D. Iron deficiency: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point New psychosis accompanied by seizures and dyskinesias requires neurologic investigation. Canadian and international guidance supports early immunotherapy, CSF antibody testing, tumour screening, and tumour removal when applicable

Flushing, secretory diarrhea, bronchospasm, metastatic neuroendocrine tumour, tricuspid or pulmonary valve disease, and right-sided heart failure indicate carcinoid syndrome with cardiac involvement.

Why the other options are less appropriate

• A. Pheochromocytoma: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Irritable bowel syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Mitral stenosis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Systemic mastocytosis confirmed by diarrhea alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Antidiarrheal medication alone does not treat serotonin secretion or the underlying tumour. ENETS guidance recommends biochemical assessment, somatostatin-analogue treatment, cardiac surveillance, and multidisciplinary management of carcinoid heart disease

5-HIAA is the principal serotonin metabolite and is commonly elevated in serotonin-secreting neuroendocrine tumours. Medication and dietary interference must be considered.

Why the other options are less appropriate

• A. Rheumatoid factor: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Serum troponin alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Urine porphobilinogen: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Serum cortisol alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Antidiarrheal medication alone does not treat serotonin secretion or the underlying tumour. ENETS guidance recommends biochemical assessment, somatostatin-analogue treatment, cardiac surveillance, and multidisciplinary management of carcinoid heart disease

Octreotide or lanreotide reduces mediator release and improves carcinoid-syndrome symptoms. Additional tumour-directed treatment depends on tumour location, extent, and progression.

Why the other options are less appropriate

• A. Loperamide as sole long-term tumour treatment: is less consistent with the full clinical context and is not the single best answer.
• B. A proton-pump inhibitor alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. An antihistamine alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Prednisone: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Antidiarrheal medication alone does not treat serotonin secretion or the underlying tumour. ENETS guidance recommends biochemical assessment, somatostatin-analogue treatment, cardiac surveillance, and multidisciplinary management of carcinoid heart disease

Substantial tryptophan diversion may reduce niacin synthesis and produce pellagra-like dermatitis, diarrhea, and neurocognitive symptoms.

Why the other options are less appropriate

• B. Vitamin B12 excess: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Copper excess: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Vitamin K toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Iron overload: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Antidiarrheal medication alone does not treat serotonin secretion or the underlying tumour. ENETS guidance recommends biochemical assessment, somatostatin-analogue treatment, cardiac surveillance, and multidisciplinary management of carcinoid heart disease

Autoimmune pancreatitis, salivary-gland enlargement, biliary involvement, and retroperitoneal fibrosis causing ureteral obstruction are classic manifestations of systemic IgG4-related disease.

Why the other options are less appropriate

• A. Sjögren syndrome alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Pancreatic cancer confirmed by serum IgG4: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Acute gallstone pancreatitis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Sarcoidosis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not label a pancreatic mass as autoimmune disease without adequately excluding malignancy. Revised diagnostic criteria combine clinical or radiologic disease, serologic findings, and characteristic pathology rather than relying on serum IgG4 alone

Characteristic histology and IgG4-positive plasma-cell infiltration support the diagnosis. Histology varies by organ and must be interpreted in the full clinical context.

Why the other options are less appropriate

• A. Linear anti-GBM deposition: is less consistent with the full clinical context and is not the single best answer.
• B. Caseating granulomas: is less consistent with the full clinical context and is not the single best answer.
• C. Amyloid deposition only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Reed–Sternberg cells: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not label a pancreatic mass as autoimmune disease without adequately excluding malignancy. Revised diagnostic criteria combine clinical or radiologic disease, serologic findings, and characteristic pathology rather than relying on serum IgG4 alone

Pancreatic, biliary, lymph-node, and retroperitoneal malignancies can resemble IgG4-related disease. Elevated serum IgG4 is neither completely sensitive nor specific.

Why the other options are less appropriate

• B. Serum IgG4 always confirms the diagnosis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Steroid response proves the diagnosis in every case: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Biopsy is used only to measure copper: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Tissue examination cannot distinguish inflammatory disorders: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not label a pancreatic mass as autoimmune disease without adequately excluding malignancy. Revised diagnostic criteria combine clinical or radiologic disease, serologic findings, and characteristic pathology rather than relying on serum IgG4 alone

Active organ-threatening disease generally requires glucocorticoid induction. Ureteral or biliary obstruction may require immediate drainage or stenting. Rituximab or other strategies may be used for selected relapsing or refractory disease.

Why the other options are less appropriate

• A. Begin pancreatic-enzyme supplements as the sole treatment: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Observe the hydronephrosis until renal failure becomes permanent: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Use an herbal diuretic for ureteral obstruction: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Perform routine abdominal manipulation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not label a pancreatic mass as autoimmune disease without adequately excluding malignancy. Revised diagnostic criteria combine clinical or radiologic disease, serologic findings, and characteristic pathology rather than relying on serum IgG4 alone

Short-bowel syndrome with colonic continuity, carbohydrate-triggered neurologic symptoms, and unexplained high-anion-gap acidosis with a normal routine lactate level strongly suggest D-lactic acidosis.

Why the other options are less appropriate

• A. Diabetic ketoacidosis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Alcohol intoxication: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Hepatic encephalopathy: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Stroke: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point A normal routine lactate does not exclude D-lactic acidosis. Reviews of D-lactic acidosis emphasize carbohydrate restriction, correction of acidosis and dehydration, and selective alteration of intestinal bacteria

D-lactate requires a specialized assay. Failure to recognize this limitation can delay diagnosis.

Why the other options are less appropriate

• A. D-lactate is measured through serum sodium: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. D-lactate causes no acidosis: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. The liver immediately removes all D-lactate: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. The anion gap is always normal: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point A normal routine lactate does not exclude D-lactic acidosis. Reviews of D-lactic acidosis emphasize carbohydrate restriction, correction of acidosis and dehydration, and selective alteration of intestinal bacteria

Treatment reduces fermentable carbohydrate reaching colonic bacteria, corrects dehydration and acidosis, and may use antibiotics to reduce D-lactate-producing organisms.

Why the other options are less appropriate

• A. Give lactated supplements: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Administer insulin for diabetic ketoacidosis: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Encourage additional sweetened drinks: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Begin prolonged fasting without nutrition support: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point A normal routine lactate does not exclude D-lactic acidosis. Reviews of D-lactic acidosis emphasize carbohydrate restriction, correction of acidosis and dehydration, and selective alteration of intestinal bacteria

Large carbohydrate loads provide substrate for colonic bacterial production of D-lactate. Nutrition must still provide adequate calories and micronutrients under specialist supervision.

Why the other options are less appropriate

• B. Unlimited refined sugar: is less consistent with the full clinical context and is not the single best answer.
• C. Elimination of all protein: is less consistent with the full clinical context and is not the single best answer.
• D. High-dose alcohol intake: is less consistent with the full clinical context and is not the single best answer.
• E. Unrestricted fructose beverages: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point A normal routine lactate does not exclude D-lactic acidosis. Reviews of D-lactic acidosis emphasize carbohydrate restriction, correction of acidosis and dehydration, and selective alteration of intestinal bacteria

The combination of chronic hepatitis C, palpable purpura, arthralgia, neuropathy, low C4, positive rheumatoid factor, and immune-complex glomerulonephritis is characteristic of mixed cryoglobulinemic vasculitis.

Why the other options are less appropriate

• A. Diabetic nephropathy: does not explain the complete pattern of history, examination findings, and available investigations.
• B. IgA vasculitis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Granulomatosis with polyangiitis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Immune thrombocytopenia: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point One negative cryoglobulin test does not exclude disease when collection and processing were inadequate. HCV-associated cryoglobulinemic vasculitis requires treatment of the infection, with rituximab and plasma exchange considered for severe organ-threatening disease

Cryoglobulins may precipitate before laboratory processing if the sample is not maintained at an appropriate warm temperature, producing a falsely negative result.

Why the other options are less appropriate

• A. Rheumatoid factor prevents testing: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. Cryoglobulins disappear whenever C4 is low: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• D. Urinary protein destroys serum cryoglobulins: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. Cryoglobulins can only be measured in urine: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point One negative cryoglobulin test does not exclude disease when collection and processing were inadequate. HCV-associated cryoglobulinemic vasculitis requires treatment of the infection, with rituximab and plasma exchange considered for severe organ-threatening disease

Eradication of hepatitis C treats the underlying antigenic driver. Mild-to-moderate disease may improve substantially after effective antiviral treatment.

Why the other options are less appropriate

• A. Long-term prednisone without treating hepatitis C: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Antibiotics: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Aspirin alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Iron supplementation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point One negative cryoglobulin test does not exclude disease when collection and processing were inadequate. HCV-associated cryoglobulinemic vasculitis requires treatment of the infection, with rituximab and plasma exchange considered for severe organ-threatening disease

Severe renal, neurologic, pulmonary, gastrointestinal, or hyperviscosity manifestations may require urgent immunosuppression and plasma exchange in addition to antiviral therapy.

Why the other options are less appropriate

• A. Observation until dialysis is permanent: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Topical corticosteroid alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Antihistamine monotherapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. High-dose vitamin C: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point One negative cryoglobulin test does not exclude disease when collection and processing were inadequate. HCV-associated cryoglobulinemic vasculitis requires treatment of the infection, with rituximab and plasma exchange considered for severe organ-threatening disease

Polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-cell disease, skin changes, elevated VEGF, edema, thrombocytosis, papilledema, and sclerotic bone lesions form the classic POEMS syndrome pattern.

Why the other options are less appropriate

• A. Guillain–Barré syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Chronic inflammatory demyelinating polyneuropathy alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Multiple myeloma with typical lytic lesions: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Diabetic neuropathy: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not diagnose CIDP alone when neuropathy is accompanied by monoclonal lambda protein, endocrinopathy, organomegaly, skin changes, and elevated VEGF. Contemporary diagnostic frameworks require polyneuropathy and a monoclonal plasma-cell disorder, with therapy directed at the underlying plasma-cell clone

The diagnostic framework requires both polyneuropathy and a monoclonal plasma-cell disorder, plus additional major and minor criteria.

Why the other options are less appropriate

• A. Hypercalcemia and lytic bone lesions: is less consistent with the full clinical context and is not the single best answer.
• B. Diabetes and hypertension: is less consistent with the full clinical context and is not the single best answer.
• D. Renal failure and anemia: is less consistent with the full clinical context and is not the single best answer.
• E. Fever and splenomegaly: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not diagnose CIDP alone when neuropathy is accompanied by monoclonal lambda protein, endocrinopathy, organomegaly, skin changes, and elevated VEGF. Contemporary diagnostic frameworks require polyneuropathy and a monoclonal plasma-cell disorder, with therapy directed at the underlying plasma-cell clone

VEGF is frequently markedly elevated and reflects disease activity. It is interpreted alongside the clinical and hematologic findings.

Why the other options are less appropriate

• A. Troponin: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Porphobilinogen: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Ceruloplasmin: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Anti-GBM antibody: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not diagnose CIDP alone when neuropathy is accompanied by monoclonal lambda protein, endocrinopathy, organomegaly, skin changes, and elevated VEGF. Contemporary diagnostic frameworks require polyneuropathy and a monoclonal plasma-cell disorder, with therapy directed at the underlying plasma-cell clone

Localized disease driven by an isolated sclerotic plasmacytoma may be treated with radiation. Diffuse or marrow-based disease generally requires systemic plasma-cell-directed therapy, with autologous stem-cell transplantation considered in eligible patients.

Why the other options are less appropriate

• B. Treat only the neuropathic pain: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Use IV immunoglobulin as routine definitive monotherapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Begin high-dose vitamin B6: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Observe until respiratory failure develops: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not diagnose CIDP alone when neuropathy is accompanied by monoclonal lambda protein, endocrinopathy, organomegaly, skin changes, and elevated VEGF. Contemporary diagnostic frameworks require polyneuropathy and a monoclonal plasma-cell disorder, with therapy directed at the underlying plasma-cell clone

Recurrent systemic mast-cell symptoms, persistently elevated baseline tryptase, characteristic skin lesions, clonal mast-cell aggregates, and a KIT mutation support systemic mastocytosis.

Why the other options are less appropriate

• A. Panic disorder: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Carcinoid syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Hereditary angioedema: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Pheochromocytoma: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not substitute antihistamines for epinephrine during cardiovascular or respiratory anaphylaxis

Anaphylaxis requires immediate intramuscular epinephrine. Antihistamines and other mediator-directed treatments are adjuncts and must not delay epinephrine.

Why the other options are less appropriate

• B. Oral antihistamine alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Intravenous corticosteroid alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Cromolyn alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Aspirin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not substitute antihistamines for epinephrine during cardiovascular or respiratory anaphylaxis

Comparison with the individual baseline is more informative than applying one universal acute tryptase threshold.

Why the other options are less appropriate

• A. A fall in total IgE: is less consistent with the full clinical context and is not the single best answer.
• B. Any tryptase value below the reference range: is less consistent with the full clinical context and is not the single best answer.
• C. A normal histamine level: is less consistent with the full clinical context and is not the single best answer.
• E. A rise in serum ferritin: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not substitute antihistamines for epinephrine during cardiovascular or respiratory anaphylaxis

Carry epinephrine auto-injectors and receive trigger-specific emergency education is the single best answer because it most closely matches the clinical context and the case’s management principles.

Case context A 46-year-old man presents after developing flushing, generalized pruritus, abdominal cramping, wheezing, and syncope following a wasp sting. He reports several previous unexplained episodes of flushing and lightheadedness.

Why the other options are less appropriate

• A. Avoid all vaccination permanently: is less consistent with the full clinical context and is not the single best answer.
• B. Depend on oral diphenhydramine during future collapse: is less consistent with the full clinical context and is not the single best answer.
• D. Use a botanical tincture instead of emergency medication: is less consistent with the full clinical context and is not the single best answer.
• E. Take aspirin before insect exposure: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not substitute antihistamines for epinephrine during cardiovascular or respiratory anaphylaxis

Recurrent nonpruritic angioedema, abdominal attacks, absent urticaria, a family history, low C4, and reduced C1-inhibitor quantity and function indicate type 1 hereditary angioedema.

Why the other options are less appropriate

• A. Histamine-mediated food allergy: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Acute urticaria: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Contact dermatitis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Panic attack: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not wait for visible respiratory distress before treating progressive laryngeal swelling